

Jairo Quiroga*, Mario Alvarado and Braulio Insuasty

Department of Chemistry, Universidad del Valle, A.A. 25360, Cali, Colombia

Manuel Noguerras, Adolfo Sánchez and Justo Cobo

Department of Inorganic and Organic Chemistry, Universidad de Jaén, E-23071 Jaén, Spain

Received February 20, 1998

This paper describes the synthesis of a new series of 7-amino-5-aryl-6-cyano-5,8-dihydropyrido[2,3-*d*]pyrimidin-4(3*H*)-ones **3** from the reaction of 6-amino-4-pyrimidinones **1** with arylidene derivatives of malonodinitrile **2**. The structure of the final compounds was determined on the basis of nmr measurements, especially by ¹H, ¹H-, ¹H, ¹³C COSY, DEPT, HMBC and HMQC experiments.

J. Heterocyclic Chem., **35**, 1309 (1998).

Introduction.

The pyrido[2,3-*d*]pyrimidines (deaza-analogs of pteridines) and their oxo derivatives deserve great interest for their potential biological and pharmacological activities [1-6], especially for their potential antitumor [7,8] and antibacterial [9,10] properties.

We have previously reported the reaction of 6-amino-4-pyrimidones with chalcones [11,12] and benzylidene derivatives of Meldrum's acid [13] as an efficient method for the synthesis of pyrido[2,3-*d*]pyrimidines. It has been our interest to examine this method and its application to the synthesis of new pyrido[2,3-*d*]pyrimidine derivatives from arylidene malonodinitrile as α,β -unsaturated component.

In this work, we studied the extension of the above reaction to 6-amino-3,4-dihydropyrimidines **1** and the benzylidene derivatives of malononitrile **2**.

Results and Discussion.


A solution of equimolar amounts of 6-amino-3,4-dihydro-4-pyrimidones **1** and **2** was refluxed in ethanol, in

the presence of catalytic amounts of triethylamine, for 1-1.5 hours. After cooling the generated precipitate was filtered off to give the corresponding 7-amino-5-aryl-6-cyano-5,8-dihydropyrido[2,3-*d*]pyrimidines **3a-f**. The new compounds were obtained in good yields (Scheme 1) as stable crystalline solids and were easily purified by recrystallization from ethanol.

The structure of compounds **3** was confirmed by spectroscopy analysis. Thus, the ir spectra of **3** measured in potassium bromide pellets show three bands for NH groups at 3240-3270 cm⁻¹ and the typical nitrile absorption at 2173-2200 cm⁻¹.

The ¹H-nmr spectra of compounds **3a-f** measured in dimethyl sulfoxide-*d*₆ (Table 1) exhibit the signals of the methyl group at 2.42-3.85 ppm and the aromatic proton signals at 7.16-8.15 ppm. There are also singlets at δ 4.43-4.75, 9.20-9.24 and 5.86-7.30 ppm respectively with a 1:1:2 relation, corresponding to 5-H, 8-NH protons of the pyrido[2,3-*d*]pyrimidinic system and the amino group (in **3a**, **3d** and **3f**, signals for 3-NH and 8-NH were not observed).

Scheme 1



	3a	3b	3c	3d	3e	3f
R ¹	H	Cl	NO ₂	H	Cl	NO ₂
X	O	O	O	S	S	S
mp °C	245	250	278	>360	335	260
Yield, %	72	72	75	68	70	70

Table 1

¹H-NMR Data of **3a-f** (δ values, Tetramethylsilane as the Internal Standard, in Dimethyl-d₆ Sulfoxide, 300 MHz)

Compound	CH ₃ X s	5-H s	3-NH [a] s	8-NH [a] s	NH ₂ [a] s	5-Ar dd
3a	3.76	4.51	[b]	[b]	7.10	7.19-7.33
3b	3.85	4.43	12.02	9.23	5.85	7.17-7.34
3c	3.77	4.72	[b]	[b]	7.27	7.46-8.22
3d	2.47	4.43	12.40	9.20	5.86	7.16-7.26
3e	2.48	4.45	12.38	9.24	5.92	7.18-7.34
3f	2.42	4.61	11.75	9.32	5.99	7.43-8.15

[a] Deuterium oxide-exchangeable. [b] Not observed.

The final elucidation of the structure of compounds **3a-f** was carried out by analysis of the ¹³C-nmr spectra (Table 2). In the ¹³C-nmr spectra of **3a-f**, a carbon signal at δ = 35.1-37.5 ppm was observed. ¹H,¹³C-COSY reveals that the proton signal belongs to the carbon atom C-5 at highest field. 2-D experiments as HMQC were very useful for the complete assigning of the carbon spectra.


Table 2

¹³C-NMR Data of **3a-f** (δ values, Tetramethylsilane as the Internal Standard, in Dimethyl-d₆ Sulfoxide, 75 MHz)

Compound	3a	3b	3c	3d	3e	3f
CH ₃ X	54.4	54.7	54.0	12.7	12.6	13.3
C-2	164.0	157.0	163.6	151.5	151.4	161.8
C-4	164.1	161.6	163.8	161.0	161.0	169.4
C-4a	89.8	92.9	88.2	95.5	95.0	90.4
C-5	35.6	37.1	35.0	37.5	37.0	35.1
C-6	58.2	56.2	56.4	56.5	56.0	56.4
C-7	160.0	151.4	159.7	151.5	151.4	159.8
C-8a	162.3	152.2	162.0	151.9	151.7	160.8
-CN	120.4	121.4	119.5	121.7	121.3	119.6
Ar						
C _i	144.3	145.5	146.4	146.5	145.3	146.6
C _{o,m}	127.4	128.0	123.8	126.9	128.1	124.0
	128.9	128.7	128.3	128.3	128.6	128.4
C _p	127.3	130.7	151.2	126.4	130.8	151.0

The formation of **3** in this reaction is assumed to proceed *via* a sequence similar to that discussed in [13-15]. These reactions must occur by Michael addition of the nucleophilic carbon atom C-5 of the pyrimidine ring towards the α,β-unsaturated system of **2** followed by cyclization of the Michael intermediate **4** (Scheme 2). The attempts of authors to work [15] to condense the 2-amino-4,6-dihydropyrimidine with methyl 2-(3'-chlorophenyl-methylene)acetoacetate resulted in nucleophilic C-5 attack and gave a product **5** with structure similar to intermediate **4**. Likewise, aminopyrimidines **1** also yield Michael adducts with α,β-unsaturated carbonyl systems as dimethyl acetylenedicarboxylate and ethyl propiolate [16].

Scheme 2



EXPERIMENTAL

Melting points were taken on a Buchi Melting Point Apparatus and are uncorrected. The ir spectra were obtained in potassium bromide pellets with a Perkin-Elmer 599B spectrometer. The ¹H and ¹³C-nmr spectra were run on a Bruker DPX 300 spectrometer operating at 300 MHz and 75 MHz respectively, using dimethyl sulfoxide-d₆ as the solvent and tetramethylsilane as the internal standard. The mass spectra were scanned on a Hewlett Packard HP Engine-5959 spectrometer (equipped with a direct inlet probe) operating at 70 eV or 30 eV. The elemental analysis have been obtained using a LECO CHNS-900 equipment.

General Procedure for the Preparation of the Substituted Pyrido[2,3-d]pyrimidines **3**.

A solution of 6-aminopyrimidine **1** (1.5 mmoles) and the corresponding arylidene derivative of malonodinitrile **2** (1.5 mmoles) in 10 ml of absolute ethanol and 1 ml of triethylamine, was stirred at reflux for 1-1.5 hours. The cyclized products **3** were isolated by cooling, followed by filtration, washed with cool ethanol, dried and recrystallized from ethanol.

7-Amino-6-cyano-5,8-dihydro-2-methoxy-5-phenylpyrido[2,3-d]pyrimidin-4(3H)-one **3a**.

This compound was obtained according to general procedure as white crystals; ir (potassium bromide): ν 3497, 3383, 3300, 3152, 2195 (CN), 1661 (CO) cm⁻¹. The mass spectrum shows the following peaks: ms: (70 eV) m/z (%) 295 (11, M⁺), 230 (10), 219 (12), 218 (100, M⁺-phenyl), 77 (18, phenyl), 69 (10), 58 (26), 52 (10), 51 (22), 44 (23), 43 (17), 39 (12).

Anal. Calcd. for C₁₅H₁₃N₅O₂: C, 61.01; H, 4.44; N, 23.72. Found: C, 61.05; H, 4.53; N, 23.80.

7-Amino-5-(4-chlorophenyl)-6-cyano-5,8-dihydro-2-methoxy-pyrido[2,3-d]pyrimidin-4(3H)-one **3b**.

This compound was obtained according to general procedure as white crystals; ir (potassium bromide): ν 3480, 3381, 3290, 3203, 2173 (CN), 1655 (CO) cm⁻¹. The mass spectrum shows the following peaks: ms: (70 eV) m/z (%) 329 (7, M⁺), 328 (11), 327 (14), 326 (20), 312 (16), 232 (13), 218 (17, M⁺-p-chlorophenyl), 111 (8, p-chlorophenyl), 84 (14), 75 (12), 73 (10), 70 (10), 69 (18), 66 (29), 58 (10), 55 (31), 53 (12), 51 (10), 50 (15), 44 (100), 43 (76), 39 (23).

Anal. Calcd. for C₁₅H₁₂N₅O₂Cl: C, 54.64; H, 3.67; N, 21.24. Found: C, 54.71; H, 3.62; N, 21.31.

7-Amino-6-cyano-5,8-dihydro-2-methoxy-5-(4-nitrophenyl)-pyrido[2,3-*d*]pyrimidin-4(3*H*)-one **3c**.

This compound was obtained according to general procedure as white crystals; ir (potassium bromide): ν 3500, 3380, 3250, 3200, 2200 (CN), 1685 (CO) cm⁻¹. The mass spectrum shows the following peaks: ms: (70 eV) *m/z* (%) 340 (M⁺, 5), 308 (1), 293 (1), 276 (2), 275 (13), 235 (1), 219 (12), 218 (100, M⁺-*p*-nitrophenyl), 201 (2), 175 (7), 161 (8), 127 (6), 106 (9), 76 (13), 58 (44), 57 (43), 43 (85).

Anal. Calcd. for C₁₅H₁₂N₆O₄: C, 52.94; H, 3.55; N, 24.70. Found: C, 52.87; H, 3.52; N, 24.77.

7-Amino-6-cyano-5,8-dihydro-2-methylthio-5-phenyl-pyrido[2,3-*d*]pyrimidin-4(3*H*)-one **3d**.

This compound was obtained according to general procedure as white crystals; ir (potassium bromide): ν 3480, 3456, 3346, 3208, 2173 (CN), 1643 (CO) cm⁻¹. The mass spectrum shows the following peaks: ms: (70 eV) *m/z* (%) 311 (13, M⁺), 309 (16), 308 (10), 235 (16), 234 (100, M⁺-phenyl), 186 (43), 140 (11), 77 (21, phenyl), 74 (17), 68 (14), 51 (29), 50 (10), 45 (14), 44 (28), 43 (42), 39 (12).

Anal. Calcd. for C₁₅H₁₃N₅OS: C, 57.86; H, 4.21; N, 22.49. Found: C, 57.79; H, 4.13; N, 22.56.

7-Amino-5-(4-chlorophenyl)-6-cyano-5,8-dihydro-2-methylthiopyrido[2,3-*d*]pyrimidin-4(3*H*)-one **3e**.

This compound was obtained according to general procedure as white crystals; ir (potassium bromide): ν 3400, 3350, 3250, 3200, 2190 (CN), 1660 (CO) cm⁻¹. The mass spectrum shows the following peaks: ms: (70 eV) *m/z* (%) 347 (3), 345 (12), 329 (9), 296 (8), 271 (3), 254 (3), 236 (7), 235 (13), 234 (100, M⁺-*p*-chlorophenyl), 186 (34), 161 (6), 131 (4), 74 (10), 43 (12).

Anal. Calcd. for C₁₅H₁₂N₅OSCl: C, 52.10; H, 3.50; N, 20.25. Found: C, 52.19; H, 3.43; N, 20.16.

7-Amino-6-cyano-5,8-dihydro-2-methylthio-5-(4-nitrophenyl)-pyrido[2,3-*d*]pyrimidin-4(3*H*)-one **3f**.

This compound was obtained according to general procedure as white crystals; ir (potassium bromide): ν 3463, 3347, 3237, 3160, 2181 (CN), 1630 (CO) cm⁻¹. The mass spectrum shows the following peaks: ms: (30 eV) *m/z* (%) 357 (3), 356 (14), 291 (12), 236 (6), 235 (16), 234 (100, M⁺-*p*-nitrophenyl), 201 (2), 186 (2), 161 (17), 144 (6), 106 (12), 91 (4), 74 (25), 43 (17).

Anal. Calcd. for C₁₅H₁₂N₆O₃S: C, 50.56; H, 3.39; N, 23.58. Found: C, 50.48; H, 3.33; N, 23.50.

Acknowledgment.

The authors thank The Colombian Institute for Science and Research (Colciencias, Project 1106-05-411-95) and Universidad del Valle for financial support of this work.

REFERENCES AND NOTES

- [1] W. J. Irwin and D. G. Wibberley, *Adv. Heterocyclic Chem.*, **10**, 149 (1969).
- [2] B. S. Herbert, R. Ferone, T. A. Herman, G. H. Hitchings, M. Barnelt and S. R. Bushby, *J. Med. Chem.*, **11**, 711 (1968).
- [3] G. L. Anderson and A. D. Broom, *J. Org. Chem.*, **42**, 997 (1977).
- [4] L. Prakash, M. Shaihl and R. L. Mital, *Pharmazie*, **44**, 490 (1989).
- [5] E. Lunt and C. C. Newton, *Comprehensive Heterocyclic Chemistry*, A. R. Katritzky and C. W. Rees, eds, Vol **3**, A. J. Boulton and A. Mc Killop, eds, Pergamon Press, Oxford, 1984, pp 199-232 and pp 260-261.
- [6] L. K. A. Rahman and S. R. Chhabra, *Med. Res. Rev.*, **8**, 95 (1988).
- [7] G. L. Anderson, J. L. Shim and A. D. Broom, *J. Org. Chem.*, **41**, 1095 (1976).
- [8] E. M. Grivsky, S. Lee, C. W. Sigel, D. S. Duch and C. A. Nichol, *J. Med. Chem.*, **23**, 327 (1987).
- [9] J. Matsumoto and S. Minami, *J. Med. Chem.*, **18**, 74 (1975).
- [10] N. Suzuki, *Chem. Pharm. Bull.*, **28**, 761 (1980).
- [11] J. Quiroga, B. Insuasty, A. Sánchez, M. Noguerras and H. Meier, *J. Heterocyclic Chem.*, **29**, 1045 (1992).
- [12] J. Quiroga, J. García, B. Insuasty, N. L. Mendoza, M. Pungo and H. Meier, *An. Quim.*, **90**, 3-4C, 300 (1994).
- [13] J. Quiroga, A. Hormaza, B. Insuasty, A. Sánchez, M. Noguerras, N. Hanold and H. Meier, *J. Heterocyclic Chem.*, **34**, 521 (1997).
- [14] R. Rodríguez, M. Suarez, E. Ochoa, A. Morales, L. González, N. Martín, M. Quinteiro, C. Seoane and J. L. Soto, *J. Heterocyclic Chem.*, **33**, 45 (1996).
- [15] A. Pastor, R. Alajarin, J. J. Vaquero, J. Alvarez-Builla, M. Fau de Casa-Juana, C. Sunkel, J. G. Priego, I. Fonseca and J. Sanz-Aparicio, *Tetrahedron*, **50**, 8085 (1994).
- [16] J. Cobo, C. Garcia, M. Melguizo, A. Sanchez, M. Noguerras, *Tetrahedron*, **50**, 10345 (1994).